Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer

• ClinicalTrials.gov Identifier: NCT01317199
• Recruitment Status: Completed
• First Posted: March 17, 2011
• Results First Posted: July 18, 2018
• Last Update Posted: April 2, 2021
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborators: Howard University; Prostate Cancer Clinical Trials Consortium
• Information provided by (Responsible Party): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Description

Brief Summary:

This research is being done to test an investigational product called Muscadine Plus in the treatment of men who have received initial therapy (surgery and or radiation, cryotherapy or brachytherapy) for prostate cancer and are experiencing a rise in their prostate-specific antigens (PSA) level.

Condition or disease	Intervention/treatment	Phase
Prostate Cancer	Drug: Muscadine Plus Grape Skin Extract; Drug: Low-dose MPX; Drug: High-dose MPX; Drug: Placebo oral capsule	Phase 1; Phase 2

Detailed Description:

In phase I the investigators are evaluating the safety of the product and checking blood levels of the active components. In phase II the investigators are evaluating the effect of MPX on PSA doubling time

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 143 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Arm 1: participants in dose-escalation phase (Phase 1) Arms 2-4: Randomized, double-blind (Phase 2); control, low-dose, high-dose
• Masking: Double (Participant, Investigator)
• Masking Description: Phase 1 (Arms 1) - open label Phase 2 (Arms 2-4) - randomized, double-blind
• Primary Purpose: Treatment
• Official Title: Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
• Study Start Date: July 2011
• Actual Primary Completion Date: November 2015
• Actual Study Completion Date: November 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Phase 1: Dose-escalation of Muscadine Plus Grape Skin Extract; Muscadine Plus Grape Skin Extract (MPX): Phase I Dose-escalation starts at 500mg daily for 1 cycle (28 days), then increased to 1000mg for 2nd cycle, then increased to 2000mg daily for 3rd cycle, then increased to 3000mg daily for 4th cycle, then increased to maximum dose of 4000mg daily for final cycle. Pills given by mouth once daily for 28 days per cycle.	Drug: Muscadine Plus Grape Skin Extract; Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
Placebo Comparator: Phase 2: Placebo control; Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).	Drug: Placebo oral capsule; Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
Experimental: Phase 2: Low-dose MPX; Randomly-assigned participants receive low-dose (500mg) MPX	Drug: Low-dose MPX; Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
Experimental: Phase 2: High-dose MPX; Randomly-assigned participants receive high-dose (4000mg) MPX	Drug: High-dose MPX; Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).

Outcome Measures

Primary Outcome Measures :

1. (Phase I) Maximum Tolerated Dose [ Time Frame: Up to 7 months post-intervention ]
   To determine the recommended dosing for Muscadine Plus and to evaluate the safety and tolerability of Muscadine Plus in prostate cancer patients with rising PSA following definitive therapy.
2. (Phase II) Prostate Specific Antigen Doubling Time (PSADT) [ Time Frame: Change from baseline to month 12 ]
   To define the effects of placebo and two different daily doses of MPX on PSADT in men who have rising PSA after initial definitive therapy for localized prostate cancer.

Secondary Outcome Measures :

1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability [ Time Frame: At month 12 post-intervention ]
   Adverse events reported verbally by patient and documented in study notes.
2. (Phase II) Proportion of Men Whose PSADT Increases Greater Than 33% [ Time Frame: At month 12 post-intervention ]
3. (Phase II) Number of Men With Greater Than 50% Reduction in PSA Compared to Baseline [ Time Frame: At month 12 post-intervention ]
   Change in PSA values drawn over study period, taken every 3 months. PSA is measured in ng/mL

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed adenocarcinoma of the prostate.
• Undergone definitive treatment (surgery, surgery with radiation therapy, cryotherapy, radiation therapy or brachytherapy) for the primary prostate tumor.
• Rising PSA on a minimum of 3 time points (including screening psa) within the 12 months prior to study initiation.
• > 18 years of age.
• Life expectancy of greater than 6 months.
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
• Testosterone level of ≥1.5 ng/mL at screening.
• Adequate kidney, liver and bone marrow function
• Agrees to abstain from other commercially available MP products while participating in this study.
• Subject's use of other dietary/herbal supplements (e.g. saw palmetto, selenium, etc) has been stable for at least 2 months prior to screening and the subject agrees not to stop or change the dose(s) while participating in the study.
• Signed a written informed consent document and agrees to comply with requirements of the study.

Exclusion Criteria:

• Known radiographic evidence of metastatic disease, except for presence of positive lymph nodes from the surgical pathology. Pelvic/intraperitoneal lymph nodes less than 2.0 cm maybe considered nonspecific and the patient would be eligible
• Receipt of any therapies that modulate testosterone levels (e.g., androgen ablative/anti-androgen therapy, 5 alpha reductase inhibitors) for a minimum of 6 months prior to study
• Prior or concomitant treatment with experimental drugs, high dose steroids, or any other cancer treatment within 4 weeks prior to the first dose of the study product
• Consumption of Muscadine Plus over the past 2 months
• Known allergy to muscadine grapes or ellagic acid
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Negative PSA doubling time (1 time point may be excluded per 3e inclusion criteria)

Contacts and Locations

Locations

United States, District of Columbia

Sibley Memorial Hospital

Washington, District of Columbia, United States, 20016

Howard University College of Medicine

Washington, District of Columbia, United States, 20060

United States, Maryland

Johns Hopkins Hospital

Baltimore, Maryland, United States, 21205

United States, Massachusetts

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02215

United States, Michigan

Karmanos Cancer Institute

Detroit, Michigan, United States, 48201

United States, New Jersey

Cancer Institute of New Jersey

New Brunswick, New Jersey, United States, 08903

United States, New York

Roswell Park Cancer Institute

Buffalo, New York, United States, 14263

Sponsors and Collaborators

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Howard University

Prostate Cancer Clinical Trials Consortium

Investigators

• Principal Investigator: Michael A Carducci, MD; Johns Hopkins University

More Information

• Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• ClinicalTrials.gov Identifier: NCT01317199
• Other Study ID Numbers: J1161
• First Posted: March 17, 2011
• Results First Posted: July 18, 2018
• Last Update Posted: April 2, 2021
• Last Verified: June 2018

Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:

Rising psa

Additional relevant MeSH terms:

Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Prostatic Diseases